StockData
Nuvation Bio Inc. logo

Nuvation Bio Inc. (NUVB) shareholders

NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30107% above fair value
$3.90+0.06 (+1.56%)

Close on Nov 17, 2026Market cap $1.37BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
66.5%
233M of 351M shares
Institutional holders
244
40 new, 25 sold out
Net institutional buying
14M
In Q2 2026
Insider trades, 12 months
1 buys · 15 sales
Net sold $8.99M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
David Hung, M.D61,269,49827.70%13D (active) amendmentMar 24, 2024
FMR LLC
Joint filing with Abigail P. Johnson (15.00%)
50,599,22515.00%13G (passive) amendmentMar 31, 2025
Abigail P. Johnson
Joint filing with FMR LLC (13.50%)
45,285,57213.50%13G (passive) amendmentDec 31, 2024
Xiangmin Cui
Joint filing with Decheng Anbio Limited (5.20%)
26,600,4968.00%13D (active)Sep 3, 2024
BlackRock, Inc.21,708,8436.40%13G (passive)Jun 30, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of NUVBValueChange% of portfolio
FMR LLC52,230,29514.88%$296.67M+240,7020.01%
BlackRock, Inc.27,630,8377.87%$156.94M+2,530,4630.00%
Decheng Capital LLC25,954,4397.39%$147.42M–20.15%
Vanguard Capital Management LLC11,919,5143.39%$67.70M+293,3160.00%
Omega Fund Management, LLC8,081,0892.30%$45.90M–24.72%
Laurion Capital Management LP7,820,0132.23%$44.42M−2,6251.14%
State Street Corp7,370,7942.10%$41.87M+585,8670.00%
Geode Capital Management, LLC6,244,8051.78%$35.48M+381,1510.00%
Duquesne Family Office LLC4,539,8001.29%$25.79M–0.49%
American Century Companies Inc4,499,6431.28%$25.56M+1,602,5650.01%
Bank Of America Corp /De/3,529,7481.01%$20.05M+309,9220.00%
Tang Capital Management LLC3,299,5570.94%$18.74M+150,0000.85%
Redmile Group, LLC3,031,0090.86%$17.22M−122,2471.16%
Vanguard Portfolio Management LLC2,688,6660.77%$15.27M+413,2200.00%
Aqr Capital Management LLC2,356,4290.67%$13.38M+360,6710.00%
Northern Trust Corp2,321,8730.66%$13.19M+318,7650.00%
Algert Global LLC2,277,3580.65%$12.94M+435,2800.15%
Hrt Financial LP2,207,7790.63%$12.54MNew0.00%
Charles Schwab Investment Management Inc2,058,8700.59%$11.69M+66,4190.00%
Dimensional Fund Advisors LP2,047,8760.58%$11.63M−4,8150.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026244233M66.5%40 / 11152 / 2524M10M
Q1 2026233221M62.8%48 / 9159 / 3746M21M
Q4 2025224212M60.3%56 / 7270 / 3324M34M
Q3 2025203221M63.0%40 / 8348 / 1722M26M
Q2 2025182225M64.1%43 / 7931 / 2027M10M
Q1 2025161207M59.1%23 / 5452 / 1921M9M
Q4 2024160198M56.3%29 / 6436 / 2241M29M
Q3 2024154188M53.4%26 / 6036 / 1859M8M
Q2 2024148153M43.6%42 / 4639 / 1727M11M
Q1 2024124137M39.0%27 / 4238 / 1713M11M
Q4 2023116135M38.5%14 / 4432 / 2318M19M
Q3 2023125137M39.0%13 / 5036 / 1210M12M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

177 funds held NUVB in Q2 2026, 43% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of NUVBValue% of fundAs of
Fidelity Growth Company Fund17,536,6014.99%$83.82M0.08%May 31, 2026
Vanguard Total Stock Market Index Fund8,849,3292.52%$50.26M0.00%Jun 30, 2026
iShares Russell 2000 ETF6,570,0591.87%$37.32M0.04%Jun 30, 2026
Fidelity Growth Company K6 Fund4,910,5631.40%$23.47M0.09%May 31, 2026
Fidelity Series Growth Company Fund4,516,4781.29%$21.59M0.09%May 31, 2026
Small Cap Growth Fund3,423,8230.98%$21.67M0.39%Jul 31, 2026
Vanguard Extended Market Index Fund2,787,9090.79%$15.84M0.02%Jun 30, 2026
Fidelity Small Cap Index Fund2,755,5760.78%$17.44M0.05%Jul 31, 2026
iShares Russell 2000 Growth ETF2,326,5680.66%$13.21M0.09%Jun 30, 2026
Select Biotechnology Portfolio1,758,5330.50%$8.41M0.16%May 31, 2026
iShares Biotechnology ETF1,743,3920.50%$9.90M0.11%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF1,427,4630.41%$8.11M1.89%Jun 30, 2026
Fidelity Extended Market Index Fund1,239,0340.35%$5.92M0.01%May 31, 2026
Vanguard Russell 2000 Index Fund1,238,0810.35%$5.92M0.03%May 31, 2026
Schwab U.S. Small-Cap ETF1,145,0770.33%$5.47M0.02%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
David HungPRESIDENT AND CEO, Director, 10% owner59,281,05416.88%Mar 3, 2026
Gary HattersleyCHIEF SCIENTIFIC OFFICER0–Aug 21, 2026
Philippe SauvageChief Financial Officer54,1300.02%Jul 17, 2026
Stacy MarkelCHIEF PEOPLE OFFICER157,5910.04%Jun 24, 2026
Kerry WentworthCHIEF REGULATORY OFFICER116,0000.03%Jun 24, 2026
Dongfang LiuCHIEF MEDICAL OFFICER68,0000.02%Apr 21, 2026
Colleen SjogrenChief Commercial Officer84,0000.02%Mar 3, 2026
David C. HanleyCHIEF TECHNICAL OPERATIONS24,0000.01%Mar 3, 2026
Moses MakunjeSEE REMARKS68,1370.02%Mar 3, 2026
Robert MashalDirector225,0000.06%Jun 11, 2026
Xiangmin CuiDirector25,954,4397.39%May 26, 2026
Robert B. BazemoreDirector5,0000.00%May 26, 2026
W. Anthony VernonDirector254,1000.07%May 26, 2026
Kathryn E. FalbergDirector250,0000.07%May 26, 2026
Kim D. BlickenstaffDirector172,1890.05%May 26, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Gary Hattersley
CHIEF SCIENTIFIC OFFICER
Aug 19, 2026Sale(10b5-1 plan)−100,000$7.09$709.00K0
Gary Hattersley
CHIEF SCIENTIFIC OFFICER
Aug 19, 2026Option exercise+100,000$1.87$187.00K100,000
Philippe Sauvage
Chief Financial Officer
Jul 15, 2026Option exercise+39,999$2.17$86.80K54,130
Philippe Sauvage
Chief Financial Officer
Jul 15, 2026Option exercise+1$1.97$254,131
Kerry Wentworth
CHIEF REGULATORY OFFICER
Jun 23, 2026Option exercise+63,000$2.93$184.59K116,000
Kerry Wentworth
CHIEF REGULATORY OFFICER
Jun 23, 2026Sale(10b5-1 plan)−63,000$6.02$379.26K53,000
Stacy Markel
CHIEF PEOPLE OFFICER
Jun 23, 2026Option exercise+34,620$1.74$60.24K157,591
Stacy Markel
CHIEF PEOPLE OFFICER
Jun 23, 2026Sale(10b5-1 plan)−125,000$6.03$753.75K32,591
Stacy Markel
CHIEF PEOPLE OFFICER
Jun 23, 2026Option exercise+90,380$1.87$169.01K122,971
Philippe Sauvage
Chief Financial Officer
Jun 23, 2026Sale(10b5-1 plan)−47,668$6.01$286.48K12,673
Philippe Sauvage
Chief Financial Officer
Jun 23, 2026Option exercise+47,668$2.17$103.44K60,341
Robert Mashal
Director
Jun 9, 2026Buy+25,000$4.73$118.25K225,000
Kerry Wentworth
CHIEF REGULATORY OFFICER
Apr 17, 2026Sale(10b5-1 plan)−36,750$5.01$184.12K53,000
Kerry Wentworth
CHIEF REGULATORY OFFICER
Apr 17, 2026Option exercise+36,750$2.93$107.68K89,750
Dongfang Liu
CHIEF MEDICAL OFFICER
Apr 17, 2026Option exercise+50,000$1.94$97.00K68,000
Dongfang Liu
CHIEF MEDICAL OFFICER
Apr 17, 2026Sale(10b5-1 plan)−50,000$5.02$251.00K18,000
Kerry Wentworth
CHIEF REGULATORY OFFICER
Apr 6, 2026Option exercise+100,000$1.87$187.00K153,000
Kerry Wentworth
CHIEF REGULATORY OFFICER
Apr 6, 2026Option exercise+100,000$1.94$194.00K253,000
Kerry Wentworth
CHIEF REGULATORY OFFICER
Apr 6, 2026Sale(10b5-1 plan)−200,000$4.52$904.00K53,000
Moses Makunje
SEE REMARKS
Feb 27, 2026Award+50,761––68,137
Dongfang Liu
CHIEF MEDICAL OFFICER
Dec 1, 2025Sale−150,000$7.82$1.17M18,000
Dongfang Liu
CHIEF MEDICAL OFFICER
Dec 1, 2025Option exercise+150,000$2.93$439.50K168,000
Dongfang Liu
CHIEF MEDICAL OFFICER
Nov 26, 2025Option exercise+10,000$3.61$36.10K28,000
Dongfang Liu
CHIEF MEDICAL OFFICER
Nov 26, 2025Sale−10,000$8.00$80.00K18,000
Dongfang Liu
CHIEF MEDICAL OFFICER
Nov 25, 2025Option exercise+10,000$3.61$36.10K28,000
Dongfang Liu
CHIEF MEDICAL OFFICER
Nov 25, 2025Sale−10,000$7.50$75.00K18,000
Dongfang Liu
CHIEF MEDICAL OFFICER
Nov 20, 2025Sale−20,000$7.00$140.00K18,000
Dongfang Liu
CHIEF MEDICAL OFFICER
Nov 20, 2025Option exercise+20,000$1.87$37.40K38,000
Gary Hattersley
CHIEF SCIENTIFIC OFFICER
Nov 20, 2025Sale−300,000$7.23$2.17M0
Gary Hattersley
CHIEF SCIENTIFIC OFFICER
Nov 20, 2025Option exercise+300,000$1.94$582.00K300,000
Gary Hattersley
CHIEF SCIENTIFIC OFFICER
Nov 20, 2025Sale−69,051$7.23$499.24K0
Gary Hattersley
CHIEF SCIENTIFIC OFFICER
Nov 20, 2025Option exercise+69,051$1.74$120.15K69,051
David C. Hanley
CHIEF TECHNICAL OPERATIONS
Nov 19, 2025Sale−200,000$7.14$1.43M24,000
David C. Hanley
CHIEF TECHNICAL OPERATIONS
Nov 19, 2025Option exercise+200,000$1.87$374.00K224,000
Dongfang Liu
CHIEF MEDICAL OFFICER
Nov 19, 2025Sale−15,000$5.10$76.50K18,000
Dongfang Liu
CHIEF MEDICAL OFFICER
Nov 19, 2025Option exercise+15,000$1.87$28.05K30,000
Dongfang Liu
CHIEF MEDICAL OFFICER
Nov 17, 2025Sale−15,000$4.77$71.55K15,000
Dongfang Liu
CHIEF MEDICAL OFFICER
Nov 17, 2025Option exercise+15,000$1.87$28.05K30,000
Gary Hattersley
CHIEF SCIENTIFIC OFFICER
Oct 27, 2025Option exercise+100,000$1.74$174.00K100,000
Gary Hattersley
CHIEF SCIENTIFIC OFFICER
Oct 27, 2025Sale(10b5-1 plan)−100,000$5.02$502.00K0
Stacy Markel
CHIEF PEOPLE OFFICER
Jun 18, 2025Buy+10,000$1.71$17.10K29,591
Philippe Sauvage
Chief Financial Officer
Jun 17, 2025Buy+4,000$1.79$7.16K9,902
Philippe Sauvage
Chief Financial Officer
Jun 16, 2025Buy+3,300$1.84$6.07K5,902
David Hung
PRESIDENT AND CEO, Director, 10% owner
Jun 16, 2025Buy+500,000$1.79$895.00K59,281,054
Colleen Sjogren
Chief Commercial Officer
Jun 16, 2025Buy+50,000$1.81$90.50K81,000
Kerry Wentworth
CHIEF REGULATORY OFFICER
Jun 16, 2025Buy+26,000$1.79$46.54K26,000
Kerry Wentworth
CHIEF REGULATORY OFFICER
Jun 16, 2025Buy+24,000$1.80$43.20K50,000
Dongfang Liu
CHIEF MEDICAL OFFICER
May 2, 2025Option exercise+20,000$1.94$38.80K32,000
Dongfang Liu
CHIEF MEDICAL OFFICER
May 2, 2025Sale(10b5-1 plan)−20,000$2.50$50.00K12,000
David Hung
PRESIDENT AND CEO, Director, 10% owner
Apr 7, 2025Buy+300,000$1.63$489.00K58,781,054
David Hung
PRESIDENT AND CEO, Director, 10% owner
Apr 4, 2025Buy+200,000$1.66$332.00K58,481,054
Robert Mashal
Director
Apr 1, 2025Buy+1,100$1.67$1.84K101,100
Robert Mashal
Director
Apr 1, 2025Buy+98,900$1.67$165.16K200,000
Junyuan Jerry Wang
CEO, ANHEART THERAPEUTICS LTD., Director
Nov 11, 2024Sale−56,361$2.89$162.88K3,866,228
Robert Mashal
Director
Oct 8, 2024Buy+99,981$2.20$219.96K100,000
Robert Mashal
Director
Oct 8, 2024Buy+19$2.20$4219
Xiangmin Cui
Director
Sep 4, 2024Conversion+5,157,900––7,611,031
Xiangmin Cui
Director
Sep 4, 2024Conversion+967,100––1,281,206
Xiangmin Cui
Director
Sep 4, 2024Conversion+12,879,200––17,062,202
Junyuan Jerry Wang
CEO, ANHEART THERAPEUTICS LTD., Director
Sep 4, 2024Conversion+2,543,600––3,922,589

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
23.43%
62M shares short
Days to cover
12.5
At 5M shares a day
Change since last report
-1.9%
From 63M shares
Short volume, 20 days
54.0%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Nuvation Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 782,277 shares on Sep 23, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Gary Hattersley
Officer
Aug 19, 2026100,000$696.00KAug 19, 2026Exercise of Stock Options
Stacy Markel
Officer
Jun 23, 2026125,000$720.00KJun 23, 2026Exercise of Stock Options
Kerry Wentworth
Officer
Jun 23, 202663,000$362.88KJun 23, 2026Exercise of Stock Options
Philippe Sauvage
Officer
Jun 23, 202647,668$274.57KJun 23, 2026Exercise of Stock Options
Kerry Wentworth
Officer
Apr 17, 202636,750$176.77KApr 17, 2026Exercise of Stock Options
Dongfang Liu
Officer
Apr 17, 202650,000$240.50KApr 17, 2026Exercise of Stock Options
Kerry Wentworth
Officer
Apr 6, 2026200,000$882.00KApr 6, 2026Exercise of Stock Options
Dongfang Liu
Officer
Dec 1, 2025150,000$1.17MDec 1, 2025Exercise of options under a registered plan
Dongfang Liu
Officer
Nov 26, 202510,000$80.00KNov 26, 2025Exercise of options under a registered plan
Dongfang Liu
Officer
Nov 25, 202510,000$75.00KNov 25, 2025Exercise of options under a registered plan
Dongfang Liu
Officer
Nov 20, 202520,000$140.07KNov 20, 2025Exercise of options under a registered plan
Gary Hattersley
Officer
Nov 20, 2025369,051$2.67MNov 20, 2025Exercise of options under a registered plan
Dongfang Liu
Officer
Nov 19, 202515,000$76.55KNov 19, 2025Exercise of options under a registered plan
David C. Hanley
Officer
Nov 19, 2025200,000$1.43MNov 19, 2025Exercise of options under a registered plan
Dongfang Liu
Officer
Nov 17, 202515,000$71.48KNov 17, 2025Exercise of options under a registered plan

See a number that looks wrong?